Online first
Komentarz
Opublikowany online: 2024-06-07
Wyświetlenia strony 20
Wyświetlenia/pobrania artykułu 2
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Komentarz do pracy Nowoczesne leczenie raka piersi — zarządzanie działaniami niepożądanymi

Sebastian Szmit12

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Bałata A, Konieczna A, Kunkiel M, et al. Nowoczesne leczenie raka piersi — zarządzanie działaniami niepożądanymi. Onkol Prakt Klin Edu.
  2. Lyon A, López-Fernández T, Couch L, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
  3. Schmid P, Cortes J, Dent R, et al. KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022; 386(6): 556–567.
  4. Cortes J, Cescon D, Rugo H, et al. Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Cancer Research. 2022; 82(4_Supplement): GS1-02-GS1–02.
  5. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021; 9(6).
  6. Dolladille C, Akroun J, Morice PM, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021; 42(48): 4964–4977.
  7. Zhang L, Reynolds KL, Lyon AR, et al. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: Primer. JACC CardioOncol. 2021; 3(1): 35–47.
  8. Awadalla M, Golden DL, Mahmood SS, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16): 1755–1764.
  9. Power JR, Alexandre J, Choudhary A, et al. International ICI-Myocarditis Registry†. Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. Circulation. 2021; 144(18): 1521–1523.
  10. Zhang L, Zlotoff DA, Awadalla M, et al. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020; 141(24): 2031–2034.
  11. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018; 72(24): 3158–3176.
  12. Palaskas NL, Segura A, Lelenwa L, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021; 23(10): 1725–1735.
  13. Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019; 140(2): 80–91.
  14. Ammirati E, Frigerio M, Adler ED, et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ Heart Fail. 2020; 13(11): e007405.
  15. Thuny F, Alexandre J, Salem JE, et al. French Working Group of Cardio-Oncology. Management of Immune Checkpoint Inhibitor-Induced Myocarditis: The French Working Group's Plea for a Pragmatic Approach. JACC CardioOncol. 2021; 3(1): 157–161.
  16. Curigliano G, Lenihan D, Fradley M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020; 31(2): 171–190.
  17. Dolladille C, Ederhy S, Sassier M, et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2020; 6(6): 865–871.
  18. Roth ME, Muluneh B, Jensen BC, et al. Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma. Am J Ther. 2016; 23(6): e1925–e1928.
  19. Weinstock C, Khozin S, Suzman D, et al. U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2017; 23(16): 4534–4539.
  20. Ball S, Ghosh RK, Wongsaengsak S, et al. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74(13): 1714–1727.
  21. McDonagh T, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  22. Kondapalli L, Bottinor W, Lenneman C. By Releasing the Brakes With Immunotherapy, Are We Accelerating Atherosclerosis? Circulation. 2020; 142(24): 2312–2315.
  23. Drobni ZD, Alvi RM, Taron J, et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020; 142(24): 2299–2311.
  24. Moik F, Chan WSE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021; 137(12): 1669–1678.
  25. Fasching PA, Bardia A, Nusch A, et al. 276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC). Ann Oncol. 2020; 31: S350–S351.
  26. Kisqali. Charakterystyja produktu leczniczego. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_pl.pdf.
  27. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993; 88(2): 782–784.
  28. Könemann H, Dagres N, Merino JL, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997–4126.
  29. Fradley MG, Moslehi J. QT Prolongation and Oncology Drug Development. Card Electrophysiol Clin. 2015; 7(2): 341–355.
  30. Coppola C, Rienzo A, Piscopo G, et al. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018; 63: 135–143.
  31. European Medicines Agency. ICH guideline E14/S7B on clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential—questions & answers. Sci Med Heal. 2020: EMA/CHMP/ICH/415588/2020.
  32. Okwuosa TM, Morgans A, Rhee JW, et al. American Heart Association Cardio-Oncology Subcommittee of the Council on Clinical Cardiology and the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular Radiology and Intervention. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. Circ Genom Precis Med. 2021; 14(3): e000082.
  33. Santoni M, Occhipinti G, Romagnoli E, et al. Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. BioDrugs. 2019; 33(6): 613–620.
  34. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018; 19(7): 904–915.
  35. Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019; 381(4): 307–316.
  36. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18): 1738–1748.
  37. Neven P, Fasching PA, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018; 36(24): 2465–2472.
  38. Slamon D, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020; 382(6): 514–524.
  39. Baselga J, Campone M, Piccart M, et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012; 366(6): 520–529.
  40. Paplomata E, Zelnak A, O'Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat. 2013; 140(3): 453–462.
  41. Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020; 31(8): 1001–1010.
  42. Tankova T, Senkus E, Beloyartseva M, et al. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers (Basel). 2022; 14(7): 1598.
  43. Gallagher E, Moore H, Lacouture M, et al. Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP). J Clin Oncol. 2022; 40(28_suppl): 422–422.



Onkologia w Praktyce Klinicznej - Edukacja